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Chronic exposure to environmentally relevant levels of simvastatin disrupts 
zebrafish brain gene signalling involved in energy metabolism 
 
Abstract 
Simvastatin (SIM), a hypocholesterolaemic drug of the statins group, is among the most 
prescribed pharmaceuticals for the prevention of cardiovascular diseases. Several studies 
have shown that lipophilic statins, as SIM, are able to cross the blood-brain barrier and 
interfere with the energy metabolism of the central nervous system in humans and 
mammalian models. In fish and other aquatic organisms, the effects of SIM on the brain 
energy metabolism are unknown, particularly following exposure to low environmentally 
relevant concentrations. Therefore, the present study aimed at investigating the effects of 
SIM on gene signalling pathways involved in brain energy metabolism of adult zebrafish 
(Danio rerio) following a chronic exposure (90 days) to environmentally relevant SIM 
concentrations ranging from 8 ng/L to 1000 ng/L. Real-Time PCR was used to determine 
the transcript levels of several genes involved in different pathways of the brain energy 
metabolism (glut1b, gapdh, acadm, accα, fasn, idh3a, cox4i1, and cox5aa) and the 
findings here reported integrated well with the ecological and biochemical responses 
obtained in a parallel study. The results showed that SIM can modulate the transcription 
of key genes involved in the mitochondrial electron transport chain, in glucose transport 
and metabolism, in fatty acid synthesis and β-oxidation. Furthermore, SIM exposure led 
to a sex-dependent transcription profile for some of the studied genes. Overall, the present 
study shows, for the first time, that SIM can modulate gene regulation of key pathways 
involved in the energy metabolism in fish brain at environmentally relevant 
concentrations.  
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Over the last decade, the detection level of pharmaceuticals in the aquatic environment 
has been increasing and several classes of pharmaceuticals are now detected at 
concentrations between ng/L to low µg/L (Arnold et al., 2014; Azzouz and Ballesteros, 
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2012; BIO Intelligence Service, 2013; Daughton, 2016; Fent, Weston and Caminada, 
2006; Rodil et al., 2012). As bioactive chemicals, pharmaceuticals are designed to 
produce biological effects at rather low concentrations, and therefore potential effects on 
non-target aquatic organisms cannot be excluded (BIO Intelligence Service, 2013, Santos 
et al., 2018). 
Simvastatin (SIM), a hypocholesterolaemic pharmaceutical of the statins class, is 
widely prescribed in developed countries to reduce cholesterol levels and prevent 
coronary heart diseases (Burg and Espenshade, 2011; Igel, Sudhop and VonBergman, 
2001; Neuparth et al., 2014). From an ecotoxicological standpoint, and considering that 
SIM use has greatly increased during the past decades, its presence on aquatic bodies is 
a matter of serious concern (Pereira et al., 2015; Santos et al., 2016). In fact, relevant 
amounts of SIM are continuously reaching the surface waters due to the lack of efficient 
mechanisms to eliminate the statins from effluents of wastewater treatment plants 
(WWTPs) (Fent, Weston and Caminada, 2006; Lapworth et al., 2012, Tete et al., 2019). 
Furthermore, SIM has been detected worldwide in WWTPs effluents and influents at 
concentrations up to 1500 ng/L and 8 µg/L, respectively (Kasprzyk-Hordern, Dinsdale 
and Guwy, 2009; Miao and Metcalfe, 2003; Ottmar, Colosi and Smith, 2012; Pereira et 
al., 2015; Pereira et al., 2016; Sousa, 2013; Verlicchi, Aukidy and Zambello, 2012). An 
estimation of 369.8 and 630 ng/L for environmental concentrations of SIM in Portuguese 
and Norwegian surface waters, respectively, has been previously reported by Grung et al. 
(2007) and Pereira et al. (2015).  
Consequently, fish can be continually exposed to SIM, and statins in general, in 
their natural habitats and several studies have reported multiple detrimental effects of 
SIM in fish (Crespo and Solé, 2016; Cunha, Santos and Ferreira, 2016; Cunha et al., 2017; 
Thorpe et al., 2004). The effects described in zebrafish (Danio rerio) include 
morphological and physiological alterations in embryos, movement and heartbeat 
reduction, disruption of detoxification mechanisms, alteration in the transcription of 
genes related to the cholesterol biosynthesis pathway, as well as, genes encoding nuclear 
receptors implicated in lipid homeostasis (RXR) and development (RAR) (Al-Habsi, 
Massarsky and Moon, 2016; Barros et al., 2018; Campos et al., 2016; Cunha, Santos and 
Ferreira, 2016; Ribeiro et al., 2015). However, despite the diversity of studies regarding 
the adverse effects of statins in aquatic vertebrates, very few mechanistic studies are 
available regarding the effects of statins besides the cholesterol branch of the mevalonate 
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(MVA) pathway. To the best of our knowledge the exception is the Eisa-Beygi et al. 
(2013) study reporting that statins perturb cerebral-vascular stability in zebrafish embryos 
due to the depletion of protein geranylgeranylation and the Gjini et al. (2011) study 
showing that statins affects vessel stability in zebrafish larvae through Tie-2 (member of 
the receptor tyrosine kinase family). Nevertheless, given the conservation status of the 
MVA pathway among vertebrates (Pertusa et al, 2007; Santos et al., 2016), it is expected 
that fish could display similar responses to those described in mammals.  
In vertebrates, this class of pharmaceuticals is well known to inhibit the enzyme 
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) which is the rate limiting 
enzyme in the MVA pathway responsible for the biosynthesis of cholesterol (Al-Habsi, 
Massarsky and Moon, 2016; Blumenthal, 2000; Endo, Kuroda and Tsujita, 1976; Fent, 
Weston and Caminada, 2006; Sehayek, et al., 1994). Cholesterol aside, the MVA pathway 
is also involved in the synthesis of other important non sterol isoprenoids, such as 
coenzyme Q and geranylgeranyl pyrophosphate (GGPP), which play an essential role in 
cellular physiology (Figure 1) (Beltowski, Wojcicka and Jamroz-Wisniewska, 2009). The 
effects of statins in the kinetics of the enzymes involved in the MVA pathway have been 
thoroughly studied in mammalian models but, to the best of our knowledge, very few 
mechanistic studies have been performed in aquatic organisms. In humans and 
mammalian models, statins have been associated with pleiotropic effects, such as 
prevention of cardiovascular diseases, anticancer activity, immunomodulation and 
neuroprotection (Chen et al., 2016; Freed-Pastor et al., 2012; Schointuch et al., 2014). 
Nonetheless, statins have also been reported to induce several adverse effects (myopathy, 
cognitive dysfunction, diabetes, among others), which have been associated with either 
the depletion of coenzyme Q, protein prenylation and dolichol (final end products of the 
MVA pathway in the non-sterol branch) or with acetyl-CoA accumulation in the cells 
through mechanisms that are linked with alterations of the energy metabolism (Figure 1) 
(Betowski, Wojcicka and Jamroz-Wisniewska, 2009; du Souich, Roederer and Dufour, 
2017; Greenwood, Steinman and Zamvil, 2006; Sirvent et al., 2012). 
Following the considerations mentioned above, the present study was performed 
to investigate the effects of SIM in the regulation of molecular pathways involved in the 
energy metabolism of the model teleost fish zebrafish. This study is a component of a 
larger investigation that consisted on the assessment of the effects of environmentally 
relevant concentrations of SIM (8ng/L to 1000ng/L) in zebrafish following a chronic 
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exposure of 90 days. Here we focus on the effects of SIM in the regulation of molecular 
pathways involved in the brain energy metabolism, while key ecological responses 
(survival, growth, reproduction and embryonic development), biochemical and molecular 
markers of lipid homeostasis in liver were reported in a previous publication – Barros et 
al. (2018).  
Zebrafish was selected to conduct this experiment since it is one of the 
recommended test species for ecotoxicological studies (Segner, 2009) and due to its close 
phylogeny with mammalians, with highly conserved genes and protein functions (Fang 
and Miller, 2012). The brain was chosen for the present study, since it is the main organ 
responsible for regulating energy homeostasis in the body. Due to its high lipophilicity, 
SIM is able to cross the blood-brain barrier (Moghadasian, 1999), making the brain an 
interesting case study, since the effects of SIM in the central nervous system are still 
poorly understood. The main substrate for energy production in the brain is glucose that 
is transported through the blood-brain barrier by the glucose transporters (glut1b), which 
gene expression may be affected by cholesterol levels (Patching, 2017; Xiuli, Meiyu and 
Guanhua, 2005) (Figure 1 ). Once inside the cell, glucose participates in glycolysis and 
produces tryptophan, a process in which the gene encoding glyceraldehyde 3-phosphate 
dehydrogenase (gapdh) plays a major role (Ganapathy-Kanniappan, 2018; Seidler, 2013). 
After being transported to the mitochondrial matrix, tryptophan produces acetyl-CoA, 
which in cases of low amounts of glucose, may be obtained by fatty acid β-oxidation 
carried out by the medium-chain acyl-CoA dehydrogenase (acadm) (Eaton, Bartlett and 
Pourfarzam, 1996; Hashimoto, 1999). As fatty acids are too big to cross the blood-brain 
barrier, these molecules are synthesized in the cytosol of brain cells from the available 
acetyl-CoA through the action of Acetyl-CoA carboxylase alpha (accα) and fatty acid 
synthase (fasn) (Lyssimachou et al., 2015) (Figure 1). Mitochondrial acetyl-CoA will 
then feed the tricarboxylic acid cycle, in which the isocitrate dehydrogenase encoding 
gene (idh3a) is essential (Findlay et al., 2018; Sazanov and Jackson, 1994), and the 
resulting products are sent to the electron transport chain. The electron transport chain is 
the main ATP producer and several MVA pathway end products are able to influence this 
process, such as ubiquinones – CoQ (essential for the maintenance of the electron 
transport between complexes (Figure 1), as well as geranylgeranyl pyrophosphate 
(GGPP) and farnesyl pyrophosphate (FPP) that have been reported to affect the complex 
IV of the electron transport chain, where the genes cytochrome c oxidase subunits 4i1 
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(cox4i1) and 5aa (cox5aa) play major roles (Arnold, 2012; Fornuskova et al., 2010; 
Kadenbach et al., 2000). (Figure 1). Following the key role of the above mentioned genes, 
in this study we screened the effects of SIM on the expression pattern of the genes 
involved in the regulation of the brain energy metabolism. 
 
 
2. Material and Methods  
2.1. Zebrafish maintenance 
Wild-type zebrafish, 50-days old, were obtained from Orniex, Portugal (purchased from 
a local supplier in Singapore). The organisms were acclimatized to laboratory conditions, 
during 15 days, in a 250 L aquarium filled with dechlorinated and filtered water with 
constant aeration. Fish were kept at 28 ± 1°C with a photoperiod of 14:10 h (light:dark) 
and fed, ad libitum, two times a day with a commercial fish diet - Tetramin (Tetra, Melle, 
Germany). The water parameters pH, ammonia and nitrates were monitored twice a week. 
 
2.2. Chronic toxicity bioassay 
The assay was carried out at the Aquatic Animal Facilities of the Interdisciplinary Centre 
of Marine and Environmental Research (CIIMAR), Portugal. The experiment was ethical 
reviewed and approved by the CIIMAR animal welfare body (ORBEA, 2010/63/EU 
Directive) according to the European Directive 2010/63/EU concerning the use of 
animals for scientific research.  
A broad description of the experimental conditions of the chronic toxicity test was 
presented in the first part of this study, which aimed at evaluating the effects of SIM in 
ecological relevant endpoints (morphometric endpoints, reproduction and embryonic 
development), biochemical (cholesterol and triglyceride levels in liver) and molecular 
markers (transcription of genes related to the cholesterol branch of the mevalonate 
pathway in the liver) (Barros et al., 2018). Briefly, the experiment consisted of five 
treatments with two replicates each: the control (0.0002% acetone), and four increasing 
nominal concentrations of SIM (8, 40, 200, and 1000 ng/L, prepared in 0.0002% acetone). 
SIM (CAS no. 79902-63-9; ≥ 97% HPLC) was obtained by Sigma Aldrich®. The 
concentrations of SIM used in the present study were based on our previous research 
(Neuparth et al., 2014), which observed a severe impact on the reproduction of the 
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amphipod Gammarus locusta, after an exposure to SIM at environmentally relevant 
concentrations (ng/L range).  
Two hundred and fifty juvenile zebrafish (25 animals per 30 L bare-bottom 
aquaria - 0.83 fish/L, randomly distributed) were chronically exposed to SIM, for 90 days, 
using a flow-through system by means of a peristaltic pump (ISM 444, ISMATEC). 
Before entering in the system, the dechlorinated tap water was heated and charcoal 
filtered. Throughout the experiment, the water flow in each aquarium was maintained at 
1.08 L per hour, whereas the SIM working solutions (8, 40, 200 and 1000 ng/L) were 
administrated directly twice a day, at 0h and 8h, with a volume equivalent to the water 
renewal. The concentration of SIM in the aquaria was analysed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) once during the bioassay, at 
T0h after the first SIM addition of the day and 8 hours later, before the second SIM 
addition of the day (T8h). At T8h, the minimum and maximum decay of SIM was 27.9% 
and 57.3% in the 8 and 1000 ng/L SIM treatments, respectively (see Barros et al. 2018). 
The water contaminated with simvastatin, before being discarded, was recirculated for 
several days in a container with an activated carbon filter and ultraviolet light. 
During the experiment, zebrafish were maintained under a 14:10 (light:dark) 
photoperiod and the water parameters such as pH, ammonia and nitrates were monitored 
twice a week (pH 7.5 ± 0.2; ammonia 0.08 ± 0.04 mg/L and nitrites 0.01 ± 0.01mg/L of) 
whereas the temperature was measured daily (28 ± 1ºC). Zebrafish were fed twice a day 
with Tetramin (Tetra, Melle, Germany), supplemented with 48-h-old live brine shrimp 
(Artemia sp.). The amount of food provided was equal for all aquaria, being adjusted 
during the bioassay according to fish development and size. At maturity, the sex ratio in 
each treatment was determined by visual inspection and confirmed at the sampling time 
by stereomicroscope observation of gonads. The registered sex ratiowas between 0.85 
and 1.50 with no statistical variation among treatments (chi square = 0.995).  
 
2.3. Sampling 
At the end of the bioassay, animals were euthanized with an overdose of tricane 
methanesulfonate (300 mg/L). Brains from both males and females (n = 8/sex) from each 
treatment were individually sampled, preserved in RNALater and stored at -80 °C until 
gene expression analysis. Liver was also sampled and used in the first part of the study 




2.4. Gene expression 
2.4.1. RNA isolation and cDNA synthesis  
RNA of eight male and eight female brains, from each treatment, was individually 
extracted by Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare), in accordance 
with the manufacturer’s protocol in a final elution volume of 25 µL RNase-free water. 
RNA quantification was accomplished on a Take3 Micro-Volume Plate Reader (Biotech 
Synergy HT) coupled with the Gen5 (version 2.0) software. RNA quality was verified by 
electrophoresis (1.5% agarose gel) and through the absorbance ratio (λ 260/λ 280 nm). 
For cDNA synthesis, the iScript™ cDNA Synthesis Kit (Bio-Rad) was used with 0.4 μg 
of total RNA extracted. 
 
2.4.2. Primer design 
Zebrafish mRNA sequences for the selected genes (glut1b, gapdh, acadm, accα, fasn, 
idh3a, cox4i1 and cox5aa) and the reference genes (rpl8 and ef1α) were obtained from 
NCBI’s database (Table 1). Specific primers were designed for qRT-PCR using the 
Primer designing tool “Primer – BLAST” (NCBI) and Beacon Designer (Premier Biosoft 
International). To confirm primer specificity, a PCR was conducted in a Tgradient 
termocycler (Biometra) and the ensuing products were run in a 1.5% agarose gel 
electrophoresis. The resulting bands of the expected size for each gene were cut and 
purified with GelPure (NzyTech), following the manufacturers’ protocol and sent for 
sequencing at GATC (Eurofins Genomics). The sequencing results were then analysed 
with VecScreen (NCBI) and Geneious R10 (Biomatters Ltd) in order to confirm the 
amplified sequence (Table 1).  
 
2.4.3. qRT-PCR 
Quantitative Reverse Transcription PCR (qRT-PCR) was used to evaluate the gene 
expression profile of selected genes involved in the regulation of the brain energy 
metabolism. For each treatment, the expression of the target genes was individually 
determined with the Mastercycler® ep realplex system (Eppendorf). Brain cDNA 
samples were amplified in 96-well optical plates, in duplicates, with 5 μL of NZYSpeedy 
qPCR Green Master Mix (2x) (NZYTech), 0.4 μL of each primer (forward and reverse) 
at 10 µM, 2 μL of cDNA at 100 ng and 2.2 μL of water for a final reaction volume of  10 
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μL. For each plate, a two-step qRT-PCR program was performed: an initial denaturation 
at 95 °C (2 min), followed by 40 cycles of amplification with denaturation at 95 °C (5 s) 
and combined annealing and extension between 58 – 62 °C (25 s) (Table 1). A melting 
curve (from 55 °C to 95 °C) was generated at the end of each run to confirm the specificity 
of the assay. The PCR products were analysed by gel electrophoresis to confirm the 
presence of single bands with the expected sizes (between 111 and 250 bp, Table 1). The 
PCR efficiency for the reference and the target genes was determined by standard curves, 
using serial dilutions of cDNA of all samples’ pools (0.064 to 200 ng of cDNA). The 
reactions efficiency ranged from 90% to 102% (Table 1) and the CTs of all genes were 
within the range of the standard curves, assuring optimal DNA amplification. The 
reference genes, rpl8 and ef1α, were used to normalize the relative transcription change 
of target genes that was calculated using the 2-∆∆Ct analysis method proposed by Livak 
and Schmittgen (2001). The control expression levels of the females were normalized to 
1 and data were then expressed as fold changes relative to female´ control. 
 
2.5. Statistical analysis 
Data were first checked for normality (Kolmogorov-Smirnov test) and homogeneity of 
variances (Levene’s test) and transformed when ANOVA assumptions were not fulfilled. 
Two-way analysis of variance (ANOVA) was then used, with SIM treatments and sex as 
independent variables. When ANOVA reached  significance, the Fisher’s least significant 
difference - LSD test - was used for multiple comparations, with SIM treatments and 
sexes being compared . The significant threshold  was set as p < 0.05. A heat-map of the 





3.1. Gene expression 
Following 90 days of SIM exposure, the two selected reference genes encoding ribosomal 
protein L8 (rpl8) and elongation factor 1 alpha (ef1α) showed no variation between 
control and exposed groups, nor between males and females (data not shown).  
In SIM exposed groups, the expression level of all tested genes involved in the 
brain energy metabolism was found to be altered in either males, females, or both, with 
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the exceptions of fasn and idh3a (Figures 2 and 3). Regarding glut1b, the gene involved 
in the glucose transport and metabolism, it was altered in a sex specific manner, being 
significantly down-regulated (4.97 fold) in males exposed to 40 ng/L of SIM, and 
significantly up-regulated (2.73 fold) in females exposed to 200 ng/L of SIM. Significant 
differences were also observed in glut1b expression between males and females for 200 
and 1000 ng/L SIM. The mRNA levels of gapdh, involved in the glycolysis, were 
significantly changed by SIM exposure in both sexes. Males presented a downregulation 
at the lowest and highest concentrations, 8 and 1000 ng/L of SIM (3.02 and 3.19 fold) 
respectively, while females had the mRNA levels decreased by 4.05 and 3.43 fold after 
exposure to 8 and 40 ng/L of SIM, respectively. Significantly differences were also 
detected for gapdh at 200 ng/L SIM when males and females were compared. The 
transcription levels of acadm, a regulator of the β-oxidation of fatty acids, responded 
significantly different in males and females. In fact, male acadm was significantly up-
regulated (2.93 fold) after exposure to 40 ng/L of SIM, while females presented a down-
regulation (2.35 fold) for the same concentration. The transcription levels of accα, 
involved in fatty acid synthesis, presented significant differences between males and 
females for 8 and 200 ng/L SIM exposure.  Regarding the genes encoding proteins of the 
electron transport chain, cox4i1 and cox5aa, the first showed a contrasting pattern 
between sexes after SIM exposure, similarly to acadm and glut1b. In fact, the cox4i1 
expression profile exhibited a similar dose-response curve to glut1b. Male cox4i1 
expression was significantly down-regulated by 2.65 and 2.44 fold after 40 and 200 ng/L 
of SIM exposure, respectively, while females presented an up-regulation by 2.57 fold 
after being exposed to 1000 ng/L of SIM. Moreover, cox4i1 presented significant 
differences between males and females for control and 40, 200, 1000 ng/L SIM. Lastly, 
mRNA levels of cox5aa were significantly down-regulated by 2.42 fold in females 
exposed to 40 ng/L of SIM. In males, the transcription of this gene did not show 
significant differences. However, similarly to females, a decrease of cox5aa was observed 
for 40 ng/L SIM exposure, however not being statistically significant (p=0.08). The 
majority of the gene expression profiles analysed in this study exhibited non-monotonic 







Several studies in mammalian models, including humans, suggest that the 
inhibition of the MVA pathway by statins induces a set of detrimental effects on the brain 
(Cibickova et al., 2008; Kannan et al., 2010; Lindberg et al., 2005; Schulz et al., 2004; 
Smolders et al., 2010; Thelen et al., 2006; Xiang and Reeves, 2009). In fact, it has been 
suggested that the effects of statins on the brain energy metabolism might be similar to 
the observed effects on skeletal muscle as both, muscle and brain, are post-mitotic tissues 
with high mitochondrial vulnerability and metabolic demand (Golomb and Evans, 2008). 
Although several energy regulatory mechanisms are conserved between fish and 
mammals (Lyssimachou et al., 2015; Soengas and Aldegunde, 2002), to the best of our 
knowledge, no studies are available on the interaction of statins with energy homeostasis 
in fish brain.  
Apart from the growing body of evidence suggesting that the imbalance of 
cholesterol homeostasis plays an important role on several diseases of the central nervous 
system (Backes and Howard, 2003; Baytan et al., 2008; Kirsch, Eckert and Mueller, 2003; 
Marz, Otten and Miserez, 2007; Schulz et al., 2004; Vance, 2012), the reduction of MVA 
pathway end-products in the non-sterol branch, such as coenzyme Q (CoQ), farnesyl 
pyrophosphate (FPP) and geranylgeranyl-pyrophosphate (GGPP) have been suggested to 
be related with an impairment on the brain energy metabolism due to these end-products 
relation with the mitochondrial electron transport chain (Figure 1) (Mans, McMahon and 
Li, 2012; Oks et al., 2018). In the mitochondria, CoQ is responsible for electron transport 
during the oxidative phosphorylation, assuring ATP production in all cell types including 
neurons (Figure 1) (Littarru and Langsjoen, 2007). Additionally, a large number of 
molecules use FPP and GGPP as lipid moieties and its depletion, due to MVA inhibition 
by statins, affects a large variety of essential intracellular signalling pathways and 
functions, including the respiratory chain activity, particularly the complex IV (Figure 1) 
(Arenas et al., 2003; Mans, McMahon and Li, 2012; Ramachandran and Wierzbicki, 
2017). In the present study, exposure to the intermediate concentrations of SIM (40 ng/L 
and/or 200 ng/L) induced significant alterations in the transcript levels of zebrafish brain 
cox4i1 and cox5aa (Figure 2). These genes have an important function in the complex IV 
(COX enzymatic complex) of the electron transport chain, (Figure 1) which is responsible 
for the maintenance of a proton gradient in the mitochondrial membrane and for the 
continuous electron flow via oxidative phosphorylation (Rousseau and Han, 2002). 
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Previous studies in humans have reported a decrease of COX activity on the skeletal 
muscle of patients treated with statins, which was associated with a depletion of FPP in 
the MVA pathway (Arenas et al., 2003; Duncan et al., 2009; Mans, McMahon and Li, 
2012). These studies disclosed that statins treatment leads to an impairment of the electron 
transport chain, limiting aerobic cellular respiration. Consequently, the cellular 
metabolism may shift from aerobic to anaerobic, which produces much lower amounts of 
ATP (De Vivo and DiMauro, 1990). Although the impairment of the electron transport 
chain affects mainly the muscle function, the brain is also highly vulnerable to 
mitochondrial disruption (De Vivo and DiMauro, 1990). Similar to the studies in humans 
mentioned above, our results reported a downregulation of cox4i1 and cox5aa which 
suggest that SIM is able to disrupt the electron transport chain in zebrafish brain. Since 
the brain is highly energy dependent, these alterations could cause meaningful adverse 
effects in fish populations, since brain is the regulatory centre of the whole body and 
small changes in the energy metabolism are expected to affect a large number of 
biological processes. 
As in mammals, fish brain relies mostly on the glucose metabolism for the 
production of acetyl-CoA, essential for the tricarboxylic acid cycle. Nowis et al. (2014) 
reported that in cultured human muscle cells SIM, as well as other statins, were able to 
alter gene transcription of glut1b limiting the glucose transport to the brain. Our results 
showed that the transcription of glut1b was altered at the intermediate SIM 
concentrations, 40 ng/L and /or 200 ng/L, (a downregulation in males and an upregulation 
in females) which suggests that glucose uptake may be altered in the brain cells. These 
finding is supported by the observed changes in gapdh mRNA levels. gapdh is known to 
be a multifunctional protein, involved in several biological processes, essential for the 
glucose metabolism by its implication in the glycolysis and glycogenesis (Figure 1) 
(Kadmiri et al., 2014; Zala et al., 2013).  When glucose is reduced, brain cells also rely 
on the fatty acid β-oxidation to obtain energy through the acetyl-CoA that participates in 
the TCA cycle (Lyssimachou et al., 2015; Soengas and Aldegunde, 2002). (Figure 1). 
Our results revealed that acadm, involved in the fatty acid β-oxidation, showed altered 
transcription levels, indicating a potential modulation of the glucose metabolism.  
This study also revealed that the effects of SIM in the transcription of the genes 
glut1b, acadm and cox4i1 are sex dependent (Figures 2 - 3). Interestingly, the first part of 
this investigation (Barros et al., 2018) also indicated sex-dependent differences for the 
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levels of cholesterol and triglycerides in zebrafish liver, which suggests that males and 
females have different lipid demands. Females tend to have a higher lipid content as an 
energy reserve in comparison to males, since female reproduction is a process demanding 
higher energy consumption (Vergauwen et al., 2010). The gene expression pattern here 
observed suggests different responses in both sexes which could have important 
implications of wild fish populations. For instance, the expression pattern of glut1b, 
cox4i1 and cox5aa, at intermediate SIM concentrations, indicates that male zebrafish are 
potentially compensating the low levels of energy associated with the downregulation of 
glut1b, cox4i1 and cox5aa by increasing fatty acid β-oxidation (upregulation of acadm). 
On the other hand, at the highest SIM concentration tested, females seem to increase brain 
energy by rising the glucose transportation into the brain through the blood-brain-barrier 
(upregulation of glut1b) and intensifying the production of ATP (upregulation of cox4i1). 
It is also possible that throughout the chronic exposure to SIM, zebrafish alternate 
between glucose transportation into the brain and fatty acid β-oxidation in order to 
maintain the energy balance in the central nervous system, which could explain the 
expression profile here presented. However, caution must be taken in the interpretation 
of these results given that only gene expression is provided and no protein activity was 
studied. Moreover, it is possible that the low SIM concentrations used in the present study 
cause fluctuations of the transcription of genes related with the brain energy metabolism 
in a time dependent manner, which highlights the importance of using multiple time-
points in gene expression studies with statins. This is an issue that should be explored in 
future research. 
It is worth noting that SIM induced non-monotonic dose-response curves 
(NMDRCs) in U and inverted U-shaped forms in many of the studied genes. This non-
monotonicity indicates that the lower SIM concentrations were able to induce more 
alterations in the transcript levels of the analysed genes. In fact, this kind of response has 
been increasingly detected in studies assessing the long-term effects of compounds, 
generally endocrine disrupting chemicals, at very low concentrations (Vandenberg et al., 
2012). However, the mechanisms behind SIM non-monotonicity are poorly understood 
and should be further studied not only in fish, but also in other taxa. Again, the first part 
of this investigation (Barros et al., 2018) has also reported the occurrence of this non-
monotonic behaviour for several zebrafish responses in liver. In fact, Barros et al. (2018) 
showed that the exposition of zebrafish to the intermediate concentrations of SIM (8, 40 
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and/or 200 ng/L), presented a down-regulation of genes involved in the cholesterol branch 
of the MVA pathway, in parallel with significant alterations in triglycerides and 
cholesterol levels in the liver, as well as in zebrafish embryogenesis, while at the highest 
SIM concentration tested (1000 ng/L) the responses were similar to the control 
conditions. 
In summary, the findings of the present study indicate that chronic exposure to 
environmentally relevant concentrations of SIM had significant impacts in the 
transcription levels of key genes involved in the brain energy metabolism of adult 
zebrafish, i.e, mitochondrial electron transport chain, glucose transport / metabolism and 
fatty acid synthesis and β-oxidation. This is of high concern given that the brain is 
particularly sensitive to alterations in the energy supply and thus adverse outcomes might 
occur since the brain is the main regulatory centre for the whole organism. The results 
here presented integrate well with the first part of this investigation (Barros et al., 2018) 
where the same SIM concentrations induced significant alterations on cholesterol and 
triglycerides levels in zebrafish liver, concomitantly with important impacts on key 
ecologically relevant endpoints (weight and embryonic development). All these findings 
might have implications for wild fish populations, given that the effects reported have 
been observed at environmentally relevant concentrations. Considering the scarcity of 
knowledge regarding the effects of SIM in fish, the environmental relevance of the current 
findings requires future research that focus in additional characterization of the impacted 
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Table 1. Sequence of primers and other parameters used for qRT-PCR (5’–3’) gene 


















rlp8 Reference NM_200713.1 
F: TTGTTGGTGTTGTTGCTGGT 
R: GGATGCTCAACAGGGTTCAT 
136 58 91 
ef1α Reference NM_131263.1 
F: TACCTACCCTCCTCTTGGTCG 
R: AACCTTTGGAACGGTGTGATTG 







135 60 91 
gapdh Glycolysis NM_001115114.1 
F: ACCAGGTTGTGTCCACTGAC 
R: AGGTCACATACACGGTTGCT 







129 60 100 
accα FA synthesis NM_001271308.1 
F: CGACAGATCATGTTCCAGGC 
R: ATGGATTGCCACAGCTTCCT 
188 60 102 
fasn FA synthesis XM_682295 
F: ATCTGTTCCTGTTCGATGGC 
R: AGCATATCTCGGCTGACGTT 
250 58 95 
idh3a TCA cycle NM_20095.2 
F: CACCCATCCATGAACCTGCT 
R: CTCTGAACAACTCCATCCACGA 

























Figure 1. Interactions between brain energy metabolism and the mevalonate (MVA) pathway. Equal 
numbers indicate interactions between MVA pathway intermediates and key genes/enzymes used in the 
present study and involved in brain energy metabolism. 
27 
 
Figure 2. Relative mRNA expression of glut1b, gapdh, acadm, accα, fasn, idh3a, cox4i1 and cox5aa in 
Danio rerio brain after 90 days of SIM exposure for males and females. Error bars indicate standard errors; 
asterisks (*) indicate significant differences from the control group and cardinals (#) indicate significant 
differences between sexes (p < 0.05) (n = 8 per sex/treatment). The data was normalised to the female 




Figure 3. Summary of the gene expression in the brain of D. rerio following 90 days of exposure to SIM. 
A) Heatmap of the mRNA expression of glut1b, gapdh, acadm, accα, fasn, idh3a, cox4i1 and cox5aa 
presented as fold-differences from the control group (fold = 1) in both males (M) and females (F). B) 










Figure 1. Interactions between brain energy metabolism and the mevalonate (MVA) 
pathway. Equal numbers indicate interactions between MVA pathway intermediates and 
key genes/enzymes used in the present study and involved in brain energy metabolism.  
Figure 2. Relative mRNA expression of glut1b, gapdh, acadm, accα, fasn, idh3a, cox4i1 
and cox5aa in Danio rerio brain after 90 days of SIM exposure for males and females. 
Error bars indicate standard errors; asterisks (*) indicate significant differences from the 
control group and cardinals (#) indicate significant differences between sexes (p < 0.05) 
(n = 8 per sex/treatment). The data was normalised to the female control (1 fold). 
 
Figure 3. Summary of the gene expression in the brain of D. rerio following 90 days of 
exposure to SIM. A) Heatmap of the mRNA expression of glut1b, gapdh, acadm, accα, 
fasn, idh3a, cox4i1 and cox5aa presented as fold-differences from the control group (fold 
= 1) in both males (M) and females (F). B) Altered gene expression (p < 0.05), for at least 
one SIM concentration. 
 
